Please login to the form below

Not currently logged in
Email:
Password:

Dr Michael Mehler joins leon-nanodrugs as CEO

He succeeds Dr Ted Odlaug

leon-nanodrugs Michael MehlerMunich-headquartered leon-nanodrugs has appointed Dr Michael Mehler as chief executive officer, succeeding Dr Ted Odlaug who moves to the supervisory board.

Dr Mehler brings over 25 years of leadership experience in the pharma and biotech industries, most recently as chief executive of SpePharm, a Switz specialty hospital products developer.

Prior to this, he was chief executive officer of Riemser Pharma, and held a number of positions at Actelion Pharmaceuticals, Merck & Co and Novartis.

Dr Hubert Birner, chairman of the leon-nanodrugs board, said: “We welcome Michael to lead leon nanodrugs on our joint journey to continued growth and internationalisation.

“We know Michael as a very experienced executive and look forward to working with him.

“We would also like to express our sincere appreciation to Ted who did a tremendously impressing job - he will obviously bring his valuable expertise to the board in his new role and continue to complement our management team.”

18th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...